Diabetes, Vol 49, Issue 6 1022-1032, Copyright © 2000 by American Diabetes Association

ARTICLES

Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats

K Isshiki, M Haneda, D Koya, S Maeda, T Sugimoto and R Kikkawa
Third Department of Medicine, Shiga University of Medical Science, Otsu, Japan.

Thiazolidinedione (TZD) compounds are widely used as oral hypoglycemic agents. Herein, we provide evidence showing that troglitazone, one of the TZD compounds, is able to prevent glomerular dysfunction in diabetic rats through a novel mechanism independent of its insulin-sensitizing action. We examined the effect of troglitazone on functional and biochemical parameters of glomeruli in streptozotocin-induced diabetic rats. Troglitazone was able to prevent not only diabetic glomerular hyperfiltration and albuminuria, but an increase in mRNA expression of extracellular matrix proteins and transforming growth factor-beta1 in glomeruli of diabetic rats, without changing blood glucose levels. Biochemically, an increase in diacylglycerol (DAG) contents and the activation of the protein kinase C (PKC)-extracellular signal-regulated kinase (ERK) pathway in glomeruli of diabetic rats were abrogated by troglitazone. The activation of DAG-PKC-ERK pathways in vitro in mesangial cells cultured under high glucose conditions was also inhibited by troglitazone. Troglitazone enhanced the activities of DAG kinase, which could metabolize DAG to phosphatidic acid, in both glomeruli of diabetic rats and mesangial cells cultured under high glucose conditions. Surprisingly, pioglitazone, another TZD compound without alpha-tocopherol moiety in its structure, also prevented the activation of the DAG-PKC pathway and activated DAG kinase in mesangial cells cultured under high glucose conditions. These results may identify the TZDs as possible new therapeutic agents for diabetic nephropathy that prevent glomerular dysfunction through the inhibition of the DAG-PKC-ERK pathway.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Kume, T. Uzu, S.-i. Araki, T. Sugimoto, K. Isshiki, M. Chin-Kanasaki, M. Sakaguchi, N. Kubota, Y. Terauchi, T. Kadowaki, et al. Role of Altered Renal Lipid Metabolism in the Development of Renal Injury Induced by a High-Fat Diet J. Am. Soc. Nephrol., October 1, 2007; 18(10): 2715 - 2723. [Abstract] [Full Text] [PDF]

				D. R. Cha, X. Zhang, Y. Zhang, J. Wu, D. Su, J. Y. Han, X. Fang, B. Yu, M. D. Breyer, and Y. Guan Peroxisome Proliferator Activated Receptor {alpha}/{gamma} Dual Agonist Tesaglitazar Attenuates Diabetic Nephropathy in db/db Mice Diabetes, August 1, 2007; 56(8): 2036 - 2045. [Abstract] [Full Text] [PDF]

				X. Yu, C. Li, X. Li, and L. Cai Rosiglitazone Prevents Advanced Glycation End Products-Induced Renal Toxicity Likely through Suppression of Plasminogen Activator Inhibitor-1 Toxicol. Sci., April 1, 2007; 96(2): 346 - 356. [Abstract] [Full Text] [PDF]

				S. Ohga, K. Shikata, K. Yozai, S. Okada, D. Ogawa, H. Usui, J. Wada, Y. Shikata, and H. Makino Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-{kappa}B activation Am J Physiol Renal Physiol, April 1, 2007; 292(4): F1141 - F1150. [Abstract] [Full Text] [PDF]

				H. Boulanger, R. Mansouri, J. F. Gautier, and D. Glotz Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies? Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2696 - 2702. [Full Text] [PDF]

				A. C. Calkin, S. Giunti, K. A. Jandeleit-Dahm, T. J. Allen, M. E. Cooper, and M. C. Thomas PPAR-{alpha} and -{gamma} agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse Nephrol. Dial. Transplant., September 1, 2006; 21(9): 2399 - 2405. [Abstract] [Full Text] [PDF]

				T. Okada, J. Wada, K. Hida, J. Eguchi, I. Hashimoto, M. Baba, A. Yasuhara, K. Shikata, and H. Makino Thiazolidinediones Ameliorate Diabetic Nephropathy via Cell Cycle-Dependent Mechanisms Diabetes, June 1, 2006; 55(6): 1666 - 1677. [Abstract] [Full Text] [PDF]

				K. B. Sotiropoulos, A. Clermont, Y. Yasuda, C. Rask-Madsen, M. Mastumoto, J. Takahashi, K. Della Vecchia, T. Kondo, L. P. Aiello, and G. L. King Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPAR{gamma} agonist's effects on edema and weight gain FASEB J, June 1, 2006; 20(8): 1203 - 1205. [Abstract] [Full Text] [PDF]

				A. Benigni, C. Zoja, S. Tomasoni, M. Campana, D. Corna, C. Zanchi, E. Gagliardini, E. Garofano, D. Rottoli, T. Ito, et al. Transcriptional Regulation of Nephrin Gene by Peroxisome Proliferator-Activated Receptor-{gamma} Agonist: Molecular Mechanism of the Antiproteinuric Effect of Pioglitazone J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1624 - 1632. [Abstract] [Full Text] [PDF]

				P. Iglesias and J. J Diez Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur. J. Endocrinol., May 1, 2006; 154(5): 613 - 621. [Abstract] [Full Text] [PDF]

				M. Omata, H. Taniguchi, D. Koya, K. Kanasaki, R. Sho, Y. Kato, R. Kojima, M. Haneda, and N. Inomata N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Ameliorates the Progression of Renal Dysfunction and Fibrosis in WKY Rats with Established Anti-Glomerular Basement Membrane Nephritis J. Am. Soc. Nephrol., March 1, 2006; 17(3): 674 - 685. [Abstract] [Full Text] [PDF]

				P. M. Hall Prevention of Progression in Diabetic Nephropathy Diabetes Spectr, January 1, 2006; 19(1): 18 - 24. [Abstract] [Full Text] [PDF]

				Y. Li, X. Wen, B. C. Spataro, K. Hu, C. Dai, and Y. Liu Hepatocyte Growth Factor Is a Downstream Effector that Mediates the Antifibrotic Action of Peroxisome Proliferator-Activated Receptor-{gamma} Agonists J. Am. Soc. Nephrol., January 1, 2006; 17(1): 54 - 65. [Abstract] [Full Text] [PDF]

				F. Pistrosch, K. Herbrig, B. Kindel, J. Passauer, S. Fischer, and P. Gross Rosiglitazone Improves Glomerular Hyperfiltration, Renal Endothelial Dysfunction, and Microalbuminuria of Incipient Diabetic Nephropathy in Patients Diabetes, July 1, 2005; 54(7): 2206 - 2211. [Abstract] [Full Text] [PDF]

				R. Oliver III, E. Friday, F. Turturro, A. Lacy, and T. Welbourne Troglitazone's rapid and sustained activation of ERK1/2 induces cellular acidosis in LLC-PK1-F+ cells: physiological responses Am J Physiol Renal Physiol, June 1, 2005; 288(6): F1257 - F1266. [Abstract] [Full Text] [PDF]

				K. Shibuya, K. Kanasaki, M. Isono, H. Sato, M. Omata, T. Sugimoto, S.-i. Araki, K. Isshiki, A. Kashiwagi, M. Haneda, et al. N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Prevents Renal Insufficiency and Mesangial Matrix Expansion in Diabetic db/db Mice Diabetes, March 1, 2005; 54(3): 838 - 845. [Abstract] [Full Text] [PDF]

				G. Gruden, G. Setti, A. Hayward, D. Sugden, S. Duggan, D. Burt, R. E. Buckingham, L. Gnudi, and G. Viberti Mechanical Stretch Induces Monocyte Chemoattractant Activity via an NF-{kappa}B-Dependent Monocyte Chemoattractant Protein-1-Mediated Pathway in Human Mesangial Cells: Inhibition by Rosiglitazone J. Am. Soc. Nephrol., March 1, 2005; 16(3): 688 - 696. [Abstract] [Full Text] [PDF]

				S. Zafiriou, S. R. Stanners, S. Saad, T. S. Polhill, P. Poronnik, and C. A. Pollock Pioglitazone Inhibits Cell Growth and Reduces Matrix Production in Human Kidney Fibroblasts J. Am. Soc. Nephrol., March 1, 2005; 16(3): 638 - 645. [Abstract] [Full Text] [PDF]

				B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines Endocr. Rev., December 1, 2004; 25(6): 971 - 1010. [Abstract] [Full Text] [PDF]

				Y. Guan Peroxisome Proliferator-Activated Receptor Family and Its Relationship to Renal Complications of the Metabolic Syndrome J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2801 - 2815. [Abstract] [Full Text] [PDF]

				F. Turturro, E. Friday, R. Fowler, D. Surie, and T. Welbourne Troglitazone Acts on Cellular pH and DNA Synthesis through a Peroxisome Proliferator-Activated Receptor {gamma}-Independent Mechanism in Breast Cancer-Derived Cell Lines Clin. Cancer Res., October 15, 2004; 10(20): 7022 - 7030. [Abstract] [Full Text] [PDF]

				B. Guo, D. Koya, M. Isono, T. Sugimoto, A. Kashiwagi, and M. Haneda Peroxisome Proliferator-Activated Receptor-{gamma} Ligands Inhibit TGF-{beta}1-Induced Fibronectin Expression in Glomerular Mesangial Cells Diabetes, January 1, 2004; 53(1): 200 - 208. [Abstract] [Full Text] [PDF]

				T. Welbourne, E. Friday, R. Fowler, F. Turturro, and I. Nissim Troglitazone acts by PPAR{gamma} and PPAR{gamma}-independent pathways on LLC-PK1-F+ acid-base metabolism Am J Physiol Renal Physiol, January 1, 2004; 286(1): F100 - F110. [Abstract] [Full Text] [PDF]

				M. Kitada, D. Koya, T. Sugimoto, M. Isono, S.-i. Araki, A. Kashiwagi, and M. Haneda Translocation of Glomerular p47phox and p67phox by Protein Kinase C-{beta} Activation Is Required for Oxidative Stress in Diabetic Nephropathy Diabetes, October 1, 2003; 52(10): 2603 - 2614. [Abstract] [Full Text] [PDF]

				G. Coates, I. Nissim, H. Battarbee, and T. Welbourne Glitazones regulate glutamine metabolism by inducing a cellular acidosis in MDCK cells Am J Physiol Endocrinol Metab, October 1, 2002; 283(4): E729 - E737. [Abstract] [Full Text] [PDF]

				T. Welbourne, G. Su, G. Coates, R. Routh, K. McCarthy, and H. Battarbee Troglitazone induces a cellular acidosis by inhibiting acid extrusion in cultured rat mesangial cells Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2002; 282(6): R1600 - R1607. [Abstract] [Full Text] [PDF]

				S. Arima, K. Kohagura, K. Takeuchi, Y. Taniyama, A. Sugawara, Y. Ikeda, M. Abe, K. Omata, and S. Ito Biphasic Vasodilator Action of Troglitazone on the Renal Microcirculation J. Am. Soc. Nephrol., February 1, 2002; 13(2): 342 - 349. [Abstract] [Full Text] [PDF]

				R. Routh, K. McCarthy, and T. Welbourne Troglitazone inhibits glutamine metabolism in rat mesangial cells Am J Physiol Endocrinol Metab, January 1, 2002; 282(1): E231 - E238. [Abstract] [Full Text] [PDF]

				K. R. Tuttle, M. E. Puhlman, S. K. Cooney, and R. A. Short Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes Am J Physiol Renal Physiol, January 1, 2002; 282(1): F103 - F112. [Abstract] [Full Text] [PDF]

				T. Welbourne, R. Routh, M. Yudkoff, and I. Nissim The Glutamine/Glutamate Couplet and Cellular Function Physiology, August 1, 2001; 16(4): 157 - 160. [Abstract] [Full Text] [PDF]

				G. Ceolotto, A. Gallo, M. Sartori, R. Valente, E. Baritono, A. Semplicini, and A. Avogaro Hyperglycemia Acutely Increases Monocyte Extracellular Signal-Regulated Kinase Activity in Vivo in Humans J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1301 - 1305. [Abstract] [Full Text]

				S. B. Nicholas, Y. Kawano, S. Wakino, A. R. Collins, and W. A. Hsueh Expression and Function of Peroxisome Proliferator-Activated Receptor-{{gamma}} in Mesangial Cells Hypertension, February 1, 2001; 37(2): 722 - 727. [Abstract] [Full Text] [PDF]

				Y. Guan, Y. Zhang, A. Schneider, L. Davis, R. M. Breyer, and M. D. Breyer Peroxisome proliferator-activated receptor-gamma activity is associated with renal microvasculature Am J Physiol Renal Physiol, December 1, 2001; 281(6): F1036 - F1046. [Abstract] [Full Text] [PDF]

				F. Zheng, A. Fornoni, S. J. Elliot, Y. Guan, M. D. Breyer, L. J. Striker, and G. E. Striker Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation Am J Physiol Renal Physiol, April 1, 2002; 282(4): F639 - F648. [Abstract] [Full Text] [PDF]